- Home
- GCTS vs VERU Comparison
GCTS vs VERU Comparison
Compare GCTS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- VERU
- Stock Information
- Founded
- GCTS 1998
- VERU 1971
- Country
- GCTS United States
- VERU United States
- Employees
- GCTS N/A
- VERU N/A
- Industry
- GCTS Blank Checks
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- VERU Health Care
- Exchange
- GCTS Nasdaq
- VERU Nasdaq
- Market Cap
- GCTS 118.9M
- VERU 108.8M
- IPO Year
- GCTS N/A
- VERU 1990
- Fundamental
- Price
- GCTS $2.49
- VERU $1.09
- Analyst Decision
- GCTS Strong Buy
- VERU Strong Buy
- Analyst Count
- GCTS 1
- VERU 4
- Target Price
- GCTS $8.00
- VERU $4.00
- AVG Volume (30 Days)
- GCTS 153.9K
- VERU 2.4M
- Earning Date
- GCTS 11-14-2024
- VERU 02-06-2025
- Dividend Yield
- GCTS N/A
- VERU N/A
- EPS Growth
- GCTS N/A
- VERU N/A
- EPS
- GCTS N/A
- VERU N/A
- Revenue
- GCTS $11,532,000.00
- VERU $16,886,419.00
- Revenue This Year
- GCTS N/A
- VERU N/A
- Revenue Next Year
- GCTS $459.37
- VERU N/A
- P/E Ratio
- GCTS N/A
- VERU N/A
- Revenue Growth
- GCTS N/A
- VERU 3.62
- 52 Week Low
- GCTS $2.12
- VERU $0.36
- 52 Week High
- GCTS $56.00
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- GCTS 50.88
- VERU 79.55
- Support Level
- GCTS $2.33
- VERU $0.70
- Resistance Level
- GCTS $2.51
- VERU $0.81
- Average True Range (ATR)
- GCTS 0.14
- VERU 0.11
- MACD
- GCTS 0.01
- VERU 0.04
- Stochastic Oscillator
- GCTS 50.91
- VERU 83.64
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.